Notice to All Deutsche Bank Securities Inc. Clients From the Securities Arbitration Law Firm of Klayman & Toskes, P.A.
March 17 2005 - 8:01AM
PR Newswire (US)
Notice to All Deutsche Bank Securities Inc. Clients From the
Securities Arbitration Law Firm of Klayman & Toskes, P.A. NEW
YORK, March 17 /PRNewswire/ -- The Law Firm of Klayman &
Toskes, P.A. ("K&T") (http://www.nasd-law.com/ ) continues to
pursue individual securities arbitration claims before the National
Association of Securities Dealers ("NASD") and the New York Stock
Exchange ("NYSE") on behalf of high net worth investors who prefer
not to participate in, and investors who are ineligible to recover
from the $433 million research analyst distribution fund created by
the Securities and Exchange Commission ("SEC"). The distribution
fund follows the decision against several brokerage firms including
Deutsche Bank Securities Inc. (NYSE:DB) by the SEC (SEC v. Deutsche
Bank Securities Inc, No. 04 Civ. 06909 WHP) for violation of the
Securities and Exchange Act of 1934 ("Exchange Act") and for
violation of NASD rules 2110, and 2210 and NYSE rules 401, 472 and
476 (a)(6). Although the market capitalization lost in excess of $4
billion, the distribution fund has only allocated $28.75 million
for the following stocks purchased through Deutsche Bank Securities
Inc. 1. Getty Images, Inc. (NYSE:GYI) Apr. 5, 02 - Jul. 4, 02 2.
Oracle Corporation (NASDAQ:ORCL) May. 31, 01 - Aug. 29, 01 3.
Transkaryotic Therapies Inc. (NASDAQ:TKTX) Jul. 13, 01 - Oct. 11,
01 4. Trimeris, Inc (NASDAQ:TRMS) Dec. 28, 01 - Mar. 28, 02 5.
Untied Therapeutics Corp. (NASDAQ:UTHR) Mar. 7, 00 - Jun. 5, 00
K&T currently represents numerous high net worth investors who
have filed individual securities arbitration claims. Investors
suffering large losses achieve an overall higher recovery rate
through arbitration than any other means. Empirical evidence shows
that when an investor suffers losses in larger amounts, usually in
excess of $100,000, an individual dispute resolution process such
as an arbitration claim filed before the NYSE or the NASD may be
the best means of recovering losses suffered. K&T has offices
in California, Florida, Nebraska, and New York and represents
investors throughout the nation. The sole purpose of this release
is to investigate, on behalf of our clients, sales practice
violations of licensed brokers at major investment firms. If you
wish to discuss this announcement or have information relevant to
our securities arbitration claims, please contact Lawrence L.
Klayman at 1-888-997-9956 or visit us on the web at
http://www.nasd-law.com/ . DATASOURCE: Klayman & Toskes, P.A.
CONTACT: Lawrence L. Klayman of Klayman & Toskes, P.A.,
+1-888-997-9956 Web site: http://www.nasd-law.com/
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Nov 2023 to Nov 2024